UCB Therapy in Acquired Brain Injury

MinYoung Kim, M.D.

Status and phase

Completed

Phase 1

Conditions

Acquired Brain Injury

Treatments

Procedure: Umbilical cord blood therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT01885663

UCBABI

Details and patient eligibility

About

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with acquired brain injury.

Full description

Acquired brain injury (ABI) means brain damage caused by events after birth, rather than as part of a genetic or congenital disorders. Those with ABI suffer from cognitive, physical, or behavioral impairments limiting their activity and participation in society. ABI results from traumatic or non-traumatic brain injury due to internal or external source (e.g. infection, brain tumor, hypoxia). Preclinical studies regarding cell therapy in animal models of ABI showed improvements of neurological dysfunction. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for patients with ABI.

Enrollment

3 patients

Sex

All

Ages

5 to 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Acquired brain injury
Duration: over 12 months
Willing to comply with all study procedure

Exclusion criteria

Medical instability including pneumonia or renal function at enrollment
Uncontrolled persistent epilepsy
Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
Not eligible according to the principal investigator